高危人群
目前没有常规的筛查项目；然而在专业中心，高危患者应当作为临床试验的一部分接受筛查。[7]Del Chiaro M, Zerbi A, Capurso G, et al. Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: a position paper from the Italian Registry. Dig Liver Dis. 2010 Sep;42(9):597-605.http://www.ncbi.nlm.nih.gov/pubmed/20627831?tool=bestpractice.com 基于初步的结果，推荐通过专业中心对有症状的家庭初次诊断胰腺癌年龄的10年前启动筛查，而且对遗传性胰腺炎患者35岁后进行筛查。[44]Greenhalf W, Neoptolemos JP. Increasing survival rates of patients with pancreatic cancer by earlier identification. Nat Clin Pract Oncol. 2006 Jul;3(7):346-7.http://www.ncbi.nlm.nih.gov/pubmed/16826198?tool=bestpractice.com 胰腺癌筛查2(CAPS2)项目证明内镜下超声在筛查胰腺癌方面有前景。[45]Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21.http://www.ncbi.nlm.nih.gov/pubmed/15224285?tool=bestpractice.com[46]Wang W, Chen S, Brune KA, et al. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol. 2007 Apr 10;25(11):1417-22.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267288/http://www.ncbi.nlm.nih.gov/pubmed/17416862?tool=bestpractice.com
